Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Information about patients/participants' diseases and previous and future treatments and
outcomes will be recorded from medical records. A sample of tumor tissue that was already
collected and stored at MD Anderson or another institution will be collected. Blood (about 4
teaspoons) will be drawn so that researchers have a sample of normal cells to use for
comparison to cancer cells, a saliva sample or a cheek cell sample may be collected instead
of the blood sample.
The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized
Cancer Therapy (IPCT) is committed to implementing personalized cancer therapy for all
patients coming to MD Anderson, transforming cancer patient management and improving
outcomes by making this approach the new standard of care. The ultimate goal is to perform
in-depth molecular characterization of all tumors, in order to tailor therapies offered and
identify best standard of care and clinical trial options.
Observational Model: Case-Only, Time Perspective: Prospective
Database of Somatic Mutations and Clinical Characteristics
Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.
Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
United States: Institutional Review Board
|UT MDACC/Regional Cancer Centers||Houston, Texas 77030|